AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30354362 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine group
Number of subjects: 115
Study 27035079 — intervention group
Group type: EXPERIMENTAL
Intervention: PTBD + 3D-CRT
Number of subjects: 37
Study 27035079 — intervention group
Group type: COMPARATOR
Intervention: PTBD only
Number of subjects: 37
Study 24936727 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day omega-3 soft gels
Number of subjects: 44
Study 24936727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22469966 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based listening interventions
Number of subjects: 162
Study 22469966 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 162
Study 20400220 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude diaries (n=130)
Number of subjects: 479
Study 20400220 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought monitoring and restructuring (n=118)
Number of subjects: 479
Study 20400220 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n=231)
Number of subjects: 479
Study 18306150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of antipsychotic treatment (haloperidol, risperidone, or olanzapine) for 4 weeks
Number of subjects: 55
Study 18306150 — intervention group
Group type: COMPARATOR
Intervention: Continued treatment with antipsychotic drugs for 4 weeks
Number of subjects: 55
Study 15655101 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led adherence support
Number of subjects: 245
Study 15655101 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 245
Study 11748949 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 12658
Study 11748949 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12658
Study 9699587 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic cardiopulmonary bypass (oxygen tension = 400 mm Hg)
Number of subjects: 40
Study 9699587 — intervention group
Group type: COMPARATOR
Intervention: Normoxic cardiopulmonary bypass (oxygen tension = 140 mm Hg)
Number of subjects: 40
Study 8017358 — intervention group
Group type: EXPERIMENTAL
Intervention: enprostil 35 micrograms twice daily
Number of subjects: 145
Study 8017358 — intervention group
Group type: EXPERIMENTAL
Intervention: enprostil 35 micrograms three times daily
Number of subjects: 145
Study 8017358 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 145
Study 2598950 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release diltiazem (diltiazem-SR) 120 mg b.i.d.
Number of subjects: 12
Study 2598950 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 100 mg b.i.d.
Number of subjects: 12
Study 4219096 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium ethane 1 hydroxy 1,1 diphosphonate (EHDP)
Number of subjects: 42
Study 4219096 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 42
Study 7446943 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg/kg
Number of subjects: 14
Study 7446943 — intervention group
Group type: EXPERIMENTAL
Intervention: thiopentone 6.0 mg/kg
Number of subjects: 14
Study 7446943 — intervention group
Group type: COMPARATOR
Intervention: nitrous oxide in oxygen
Number of subjects: 14
Study 31823556 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP injection group (group A)
Number of subjects: 90
Study 31823556 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP covered group (group B)
Number of subjects: 90
Study 31823556 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 90
Study 28327108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic Scalpel (USS)
Number of subjects: 80
Study 28327108 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 80
Study 26059497 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/thymol-containing antibacterial varnish (Cervitec(®) Plus; CV group) applied quarterly
Number of subjects: 189
Study 26059497 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (Fluor Protector; FV group) applied biannually plus biannual treatments with placebo varnish
Number of subjects: 189
Study 23916324 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 40
Study 23916324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23916324 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (among cigarette smokers)
Number of subjects: 40
Study 21497318 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week supervised hip flexor stretching program
Number of subjects: 82
Study 21497318 — intervention group
Group type: COMPARATOR
Intervention: 10-week shoulder abductor stretching program
Number of subjects: 82
Study 20377818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy (rosemary and lemon essential oils in the morning, lavender and orange in the evening)
Number of subjects: 28
Study 17199068 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (n = 99)
Number of subjects: 200
Study 17199068 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 200
Study 17199068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 101)
Number of subjects: 200
Study 15030181 — intervention group
Group type: EXPERIMENTAL
Intervention: Clivarin
Number of subjects: 111
Study 15030181 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 111
Study 11586996 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 7 days
Number of subjects: 50
Study 11586996 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg for 7 days
Number of subjects: 50
Study 9832348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50-150 mg
Number of subjects: 160
Study 9832348 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 75-225 mg
Number of subjects: 160
Study 9832348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 160
Study 9832348 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 160
Study 9832348 — intervention group
Group type: COMPARATOR
Intervention: Sertraline and Amitriptyline
Number of subjects: 160
Study 8016944 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 170
Study 8016944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 2643773 — intervention group
Group type: EXPERIMENTAL
Intervention: BM 13,177 (thromboxane-receptor antagonist)
Number of subjects: 10
Study 2643773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2643773 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (20 mg twice daily for four weeks)
Number of subjects: 10
Study 4206181 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 14
Study 4206181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30665608 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CBT
Number of subjects: 180
Study 30665608 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CBT + CC
Number of subjects: 180
Study 30665608 — intervention group
Group type: COMPARATOR
Intervention: E-TAU
Number of subjects: 180
Study 27873453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy using the Thinking Skills for Work program combined with supported employment.
Number of subjects: 0
Study 27873453 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study 26072109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab every 2 weeks (80 mg starting dose, then 80 mg every 2 weeks)
Number of subjects: 2570
Study 26072109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 weeks (80 mg starting dose, then 80 mg every 4 weeks)
Number of subjects: 2570
Study 26072109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2570
Study 26072109 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg twice weekly)
Number of subjects: 2570
Study 26072109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab every 2 weeks
Number of subjects: 2570
Study 26072109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 weeks
Number of subjects: 2570
Study 26072109 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 2570
Study 26072109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (both regimens)
Number of subjects: 2570
Study 24063420 — intervention group
Group type: EXPERIMENTAL
Intervention: α-galactosidase
Number of subjects: 52
Study 24063420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21332456 — intervention group
Group type: EXPERIMENTAL
Intervention: Product C
Number of subjects: 121
Study 21332456 — intervention group
Group type: EXPERIMENTAL
Intervention: Product D
Number of subjects: 121
Study 21332456 — intervention group
Group type: EXPERIMENTAL
Intervention: Product A
Number of subjects: 121
Study 21332456 — intervention group
Group type: EXPERIMENTAL
Intervention: Products A, B, and D
Number of subjects: 121
Study 21332456 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 121
Study 19476198 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling and a novel medication
Number of subjects: 753
Study 17346614 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging group (n=26)
Number of subjects: 56
Study 17346614 — intervention group
Group type: COMPARATOR
Intervention: Conventional screening group
Number of subjects: 56
Study 17346614 — intervention group
Group type: EXPERIMENTAL
Intervention: Study participation (both groups)
Number of subjects: 56
Study 15054168 — intervention group
Group type: EXPERIMENTAL
Intervention: Small media campaign (role model story posters, billboards, and other merchandise)
Number of subjects: 1630
Study 15054168 — intervention group
Group type: EXPERIMENTAL
Intervention: Small media campaign
Number of subjects: 1630
Study 15054168 — intervention group
Group type: COMPARATOR
Intervention: Comparison zip codes (control)
Number of subjects: 1630
Study 12205253 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of oral feeding (initiated 48 hours after achieving full tube feeding, 120 kcal/kg/d)
Number of subjects: 29
Study 12205253 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral feeding management left to discretion of attending physicians)
Number of subjects: 29
Study 12205253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 9839763 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl (5 mg)
Number of subjects: 21
Study 9839763 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (200 mg)
Number of subjects: 21
Study 8018372 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation with 1 Gy 3 times a day to a total of 84 Gy
Number of subjects: 168
Study 8018372 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment 2 Gy once a day to a total of 64 Gy
Number of subjects: 168
Study 8018372 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated group
Number of subjects: 168
Study 2491863 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc (50 mg)
Number of subjects: 18
Study 2491863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 790294 — intervention group
Group type: EXPERIMENTAL
Intervention: New meditation technique using a home-study workbook manual
Number of subjects: 159
Study 790294 — intervention group
Group type: COMPARATOR
Intervention: Customary meditational techniques
Number of subjects: 159
Study 31845316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine/morphine (12.5 mg bupivacaine/300 μg morphine)
Number of subjects: 155
Study 31653138 — intervention group
Group type: EXPERIMENTAL
Intervention: Filial therapy
Number of subjects: 32
Study 31653138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training, only individual counseling)
Number of subjects: 32
Study 28168715 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 86-5047
Number of subjects: 110
Study 28168715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 25835462 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted multi‐component intervention
Number of subjects: 95
Study 22592540 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to web-based tutorial (Child Health Matters, CHM)
Number of subjects: 0
Study 22592540 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (delayed access)
Number of subjects: 0
Study 22592540 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tutorial (Child Health Matters, CHM)
Number of subjects: 0
Study 21783443 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin ideal video
Number of subjects: 138
Study 21783443 — intervention group
Group type: COMPARATOR
Intervention: Neutral video
Number of subjects: 138
Study 19968215 — intervention group
Group type: COMPARATOR
Intervention: Late surgical group (surgery >=325 days)
Number of subjects: 42
Study 19968215 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical group (surgery 324 days prior)
Number of subjects: 42
Study 17958901 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-116800 25 mg, taken twice daily for 12 months
Number of subjects: 401
Study 17958901 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-116800 50 mg, taken twice daily for 12 months
Number of subjects: 401
Study 17958901 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-116800 100 mg, taken twice daily for 12 months
Number of subjects: 401
Study 17958901 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-116800 200 mg, taken twice daily for 12 months
Number of subjects: 401
Study 17958901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 17958901 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-116800 (all doses combined)
Number of subjects: 401
Study 17958901 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-116800 (200 mg group)
Number of subjects: 401
Study 17958901 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-116800 (two highest dose groups)
Number of subjects: 401
Study 15250819 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11716450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 200 mg/day for 3 days in 500 ml of saline over 3‐4 hours
Number of subjects: 36
Study 11716450 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 36
Study 9378191 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI patients at 6 weeks post-event
Number of subjects: 1941
Study 9378191 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI patients at 6 months post-event
Number of subjects: 1941
Study 9378191 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation of quality of life and health
Number of subjects: 1941
Study 9378191 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with AMI
Number of subjects: 1941
Study 9378191 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with AMI
Number of subjects: 1941
Study 8329676 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo/meal
Number of subjects: 10
Study 8329676 — intervention group
Group type: COMPARATOR
Intervention: Placebo/no meal
Number of subjects: 10
Study 8329676 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine/meal
Number of subjects: 10
Study 3755516 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital administered to mothers in doses sufficient to achieve blood levels of 15 to 40 micrograms/mL
Number of subjects: 150
Study 3755516 — intervention group
Group type: COMPARATOR
Intervention: No antenatal treatment (control group)
Number of subjects: 150
Study 3755516 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital administered to mothers
Number of subjects: 150
Study 28942461 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Thyroidectomy (TT)
Number of subjects: 600
Study 28942461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dunhill Operation (DO)
Number of subjects: 600
Study 28942461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Subtotal Thyroidectomy (BST)
Number of subjects: 600
Study 26363446 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-frame email intervention
Number of subjects: 220
Study 26363446 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-frame email intervention
Number of subjects: 220
Study 26363446 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term consequence email intervention
Number of subjects: 220
Study 26363446 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term consequence email intervention
Number of subjects: 220
Study 25169488 — intervention group
Group type: EXPERIMENTAL
Intervention: rh‐endostatin + DP regimen
Number of subjects: 20
Study 25169488 — intervention group
Group type: COMPARATOR
Intervention: single chemotherapy
Number of subjects: 20
Study 23195004 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia + general anesthesia
Number of subjects: 46
Study 23195004 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 46
Study 20951443 — intervention group
Group type: COMPARATOR
Intervention: Group P (propofol, fentanyl, succinylcholine)
Number of subjects: 360
Study 20951443 — intervention group
Group type: EXPERIMENTAL
Intervention: Group J (propofol, fentanyl, succinylcholine + manual jet ventilation with Manujet III)
Number of subjects: 360
Study 20951443 — intervention group
Group type: COMPARATOR
Intervention: Group S (propofol and γ‐hydroxybutyrate sodium)
Number of subjects: 360
Study 17628435 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone, 30 mg/day
Number of subjects: 73
Study 17628435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 15668419 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (IFNbeta‐1a), administered once-weekly via intramuscular injection.
Number of subjects: 386
Study 11978276 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral analgesia (20 mg every 4 hours, additional 10 mg every 2 hours as needed)
Number of subjects: 227
Study 11978276 — intervention group
Group type: COMPARATOR
Intervention: Traditional parenteral analgesia (parenteral morphine via PCA pump with basal dose of 0.5 mg/h and PCA dose of 1 mg)
Number of subjects: 227
Study 10544763 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic axillary lymphadenectomy after liposuction
Number of subjects: 152
Study 10544763 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical lymphadenectomy
Number of subjects: 152
Study 7557770 — intervention group
Group type: EXPERIMENTAL
Intervention: Guttapercha
Number of subjects: 500
Study 7557770 — intervention group
Group type: COMPARATOR
Intervention: Titan pins
Number of subjects: 500
Study 1351127 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 50
Study 1351127 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 50
Study 3909118 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 9
Study 3909118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30009473 — intervention group
Group type: EXPERIMENTAL
Intervention: Proenkephalin (PENK) measured at baseline and on day 1 after contrast media administration
Number of subjects: 111
Study 30009473 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta PENK (change in PENK levels)
Number of subjects: 111
Study 30009473 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve (AUC) for prediction of AKI by day 1 PENK
Number of subjects: 111
Study 30009473 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve (AUC) for prediction of AKI by delta PENK
Number of subjects: 111
Study 27534729 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured elaborative feedback during visual shade matching
Number of subjects: 60
Study 27534729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no elaborative feedback)
Number of subjects: 60
Study 26270115 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural ultrasound-guided paramedian technique
Number of subjects: 100
Study 26270115 — intervention group
Group type: COMPARATOR
Intervention: Conventional landmark-guided midline approach
Number of subjects: 100
Study 23591789 — intervention group
Group type: EXPERIMENTAL
Intervention: DA+GO (daunorubicin 45 mg/m(2) on days 1-3, cytarabine 100 mg/m(2) continuous infusion on days 1-7, GO 6 mg/m(2) on day 4)
Number of subjects: 637
Study 23591789 — intervention group
Group type: COMPARATOR
Intervention: DA (daunorubicin 60 mg/m(2) on days 1-3, cytarabine alone)
Number of subjects: 637
Study 23591789 — intervention group
Group type: EXPERIMENTAL
Intervention: DA+GO (postconsolidation therapy with 3 doses of GO 5 mg/m(2) every 28 days)
Number of subjects: 637
Study 23591789 — intervention group
Group type: COMPARATOR
Intervention: DA (postconsolidation therapy with no additional therapy)
Number of subjects: 637
Study 23591789 — intervention group
Group type: EXPERIMENTAL
Intervention: DA+GO
Number of subjects: 637
Study 23591789 — intervention group
Group type: COMPARATOR
Intervention: DA
Number of subjects: 637
Study 23591789 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconsolidation GO
Number of subjects: 637
Study 20874057 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking Mats
Number of subjects: 5
Study 20874057 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbally structured communication
Number of subjects: 5
Study 20874057 — intervention group
Group type: COMPARATOR
Intervention: Unstructured communication
Number of subjects: 5
Study 18378631 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride, 1 to 4 mg
Number of subjects: 543
Study 18378631 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone, 15 to 45 mg
Number of subjects: 543
Study 18378631 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 543
Study 18378631 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 543
Study 16616230 — intervention group
Group type: EXPERIMENTAL
Intervention: edifoligide
Number of subjects: 1404